Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKZF2 | Q9UKS7 | 7/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 9/20 | 0.39 |
| ▸ | HTR2B | P41595 | 9/20 | 0.39 |
| ▸ | HTR2A | P28223 | 8/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23880784 | 0.86 | PARP1 (0.48) | IKZF2PARP1HTR2CHTR2BHTR2A | |
| SCHEMBL26106859 | 0.84 | IKZF2 (0.43) | IKZF2PARP1HTR2CHTR2BHTR2A | |
| SCHEMBL31482759 | 0.84 | PARP1 (0.47) | IKZF2PARP1HTR2CHTR2BHTR2A | |
| SCHEMBL23880766 | 0.84 | PARP1 (0.47) | IKZF2PARP1HTR2CHTR2BHTR2A | |
| SCHEMBL26110225 | 0.83 | PARP1 (0.44) | IKZF2PARP1HTR2CHTR2BHTR2A | |
| SCHEMBL26111658 | 0.82 | PARP1 (0.42) | IKZF2PARP1HTR2CHTR2BHTR2A | |
| SCHEMBL23880776 | 0.81 | PARP1 (0.43) | IKZF2PARP1HTR2CHTR2BHTR2A | |
| SCHEMBL26107285 | 0.81 | PARP1 (0.45) | IKZF2PARP1HTR2CHTR2BHTR2A | |
| SCHEMBL26111300 | 0.80 | PARP1 (0.45) | IKZF2PARP1HTR2CHTR2BHTR2A | |
| SCHEMBL20766606 | 0.79 | IKZF2 (0.70) | IKZF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321067-A1 | DOSING REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321067-A1 | DOSING REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | IKZF1, IKZF2, IKZF3 | IKZF2 2/4885PARP1 1183/4885HTR2C 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.